ZSTK474Potent PI3K inhibitor CAS# 475110-96-4 |
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 475110-96-4 | SDF | Download SDF |
PubChem ID | 11647372 | Appearance | Powder |
Formula | C19H21F2N7O2 | M.Wt | 417.41 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 2 mg/mL (4.79 mM; Need ultrasonic) | ||
Chemical Name | 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]morpholine | ||
SMILES | C1COCCN1C2=NC(=NC(=N2)N3C4=CC=CC=C4N=C3C(F)F)N5CCOCC5 | ||
Standard InChIKey | HGVNLRPZOWWDKD-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H21F2N7O2/c20-15(21)16-22-13-3-1-2-4-14(13)28(16)19-24-17(26-5-9-29-10-6-26)23-18(25-19)27-7-11-30-12-8-27/h1-4,15H,5-12H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | ZSTK474 is inhibitor of class I PI3K isoforms with an IC50 of 37 nM. | ||||||
Targets | PI3Kδ | PI3Kα | PI3K | PI3Kβ | PI3Kγ | ||
IC50 | 4.6 nM | 16 nM | 37 nM | 44 nM | 49 nM |
ZSTK474 Dilution Calculator
ZSTK474 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3957 mL | 11.9786 mL | 23.9573 mL | 47.9145 mL | 59.8932 mL |
5 mM | 0.4791 mL | 2.3957 mL | 4.7915 mL | 9.5829 mL | 11.9786 mL |
10 mM | 0.2396 mL | 1.1979 mL | 2.3957 mL | 4.7915 mL | 5.9893 mL |
50 mM | 0.0479 mL | 0.2396 mL | 0.4791 mL | 0.9583 mL | 1.1979 mL |
100 mM | 0.024 mL | 0.1198 mL | 0.2396 mL | 0.4791 mL | 0.5989 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
ZSTK474 strongly inhibits the growth of tumor cells by direct inhibition activity of PI3K, which includes all isoforms of class I PI3K with IC50 values of 16 nM, 44 nM, 49 nM, and 4.6 nM for PI3Kα, PI3-Kβ, PI3-Kγ, PI3-Kδ, respectively.[1]
PI3Ks are a family of enzymes, which phosphorylate the 3‘- OH position of the inositol ring of phosphoinositides.PI3Ks are divided into three classes based on the structural features and in vitro lipid substrate specificity. The three class-Ia PI3-ks (p110 α / β / δ ) and the sole class-Ib PI3K (p110 γ ) couple growth factor receptors and G-protein-coupled receptors, respectively, to a wide range of downstream pathways. Signal transduction via the PI3K/Akt pathway is essential for regulating cellular activities, such as proliferation, survival, migration, motility and tumorigenesis, in diverse cell types.[2]
ZSTK474 is a potent ATP-competitive pan class I PI3K inhibitor, which has high selectivity over other classes of PI3K and protein kinases. ZSTK474 also inhibited the bone-resorbing activity of mature osteoclasts. Experiments revealed that 0.1μM of ZSTK474 completely prevented pit formation by osteoclasts. Moreover, the IC50 values for PI3Kα, PI3-Kβ, PI3-Kγ, PI3-Kδ are 16 nM, 44 nM,49 nM, and 4.6 nM, respectively.[1]
Melanoma cells injected BDF 1 mice were orally administrated ZSTK474 daily at 100, 200, or 400 mg/kg of body weight from days 0 to 13. By measuring the volume of tumor, the outcomes showed that ZSTK474 administered orally to mice had strong antitumor activity against human cancer xenografts without toxic effects in vital organs. Akt phosphorylation was decreased in xenograft tumors after oral administration of ZSTK474. [3]
References:
1.Toyama S, Tamura N, Haruta K, et al. Research article Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice[J]. 2010.
2.Marone R, Cmiljanovic V, Giese B, et al. Targeting phosphoinositide 3-kinase—moving towards therapy[J]. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 2008, 1784(1): 159-185.
3.Yaguchi S, Fukui Y, Koshimizu I, et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor[J]. Journal of the National Cancer Institute, 2006, 98(8): 545-556.
- Tivozanib (AV-951)
Catalog No.:BCC1179
CAS No.:475108-18-0
- NS 304
Catalog No.:BCC7661
CAS No.:475086-01-2
- Nuciferine
Catalog No.:BCN1223
CAS No.:475-83-2
- Glaucine
Catalog No.:BCN2550
CAS No.:475-81-0
- Aristolochic acid B
Catalog No.:BCN6263
CAS No.:475-80-9
- Liriodenine
Catalog No.:BCN5532
CAS No.:475-75-2
- (+)-Isocorynoline
Catalog No.:BCN2361
CAS No.:475-67-2
- H-N-Me-Pro-OH
Catalog No.:BCC3351
CAS No.:475-11-6
- SB 657510
Catalog No.:BCC7713
CAS No.:474960-44-6
- ST 91
Catalog No.:BCC7436
CAS No.:4749-61-5
- 2,16-Kauranediol 2-O-beta-D-allopyranoside
Catalog No.:BCN1436
CAS No.:474893-07-7
- Monomethyl auristatin E
Catalog No.:BCC1775
CAS No.:474645-27-7
- Galnon
Catalog No.:BCC5871
CAS No.:475115-35-6
- BAN ORL 24
Catalog No.:BCC1398
CAS No.:475150-69-7
- 2-Methylthioadenosine diphosphate trisodium salt
Catalog No.:BCC5794
CAS No.:475193-31-8
- A-317491
Catalog No.:BCC1320
CAS No.:475205-49-3
- Sorafenib Tosylate
Catalog No.:BCC3654
CAS No.:475207-59-1
- Nogo-66 (1-40)
Catalog No.:BCC5862
CAS No.:475221-20-6
- CORM-3
Catalog No.:BCC5108
CAS No.:475473-26-8
- Aleglitazar
Catalog No.:BCC1337
CAS No.:475479-34-6
- NVP-ADW742
Catalog No.:BCC4553
CAS No.:475488-23-4
- NVP-AEW541
Catalog No.:BCC1180
CAS No.:475489-16-8
- MCL 0020
Catalog No.:BCC6025
CAS No.:475498-26-1
- Isotretinoin
Catalog No.:BCC2284
CAS No.:4759-48-2
ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells.[Pubmed:26918351]
Oncotarget. 2016 Apr 12;7(15):19897-909.
Multifaceted activities of class I phosphatidylinositol 3-kinase (PI3K) inhibitor ZSTK474 were investigated on human breast cancer cell MCF-7. ZSTK474 inhibited proliferation of MCF-7 cells potently. Flow cytometric analysis indicated that ZSTK474 induced cell cycle arrest at G1 phase, but no obvious apoptosis occurred. Western blot analysis suggested that blockade of PI3K/Akt/GSK-3beta/cyclin D1/p-Rb pathway might contribute to the G1 arrest induced. Moreover, we demonstrated that ZSTK474 induced autophagy in MCF-7 cells by use of various assays including monodansylcadaverine (MDC) staining, transmission electron microscopy (TEM), tandem mRFP-GFP-LC3 fluorescence microscopy, and western blot detection of the autophagy protein markers of LC3B II, p62 and Atg 5. Inhibition of class I PI3K and the downstream mTOR might be involved in the autophagy-inducing effect. Combinational use of ZSTK474 and autophagy inhibitors enhanced cell viability, suggesting ZSTK474-induced autophagy might contribute to the antitumor activity. Our report supports the application of ZSTK474, which is being evaluated in clinical trials, for breast cancer therapy.
In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.[Pubmed:27194941]
Int J Biol Sci. 2016 Apr 8;12(6):631-8.
Chronic myelogenous leukemia (CML) is a malignant hematological disorder mainly caused by the Bcr-Abl tyrosine kinase. While Bcr-Abl inhibitors including Imatinib showed antitumor efficacy on many CML patients, resistance was frequently reported in recent years. Therefore, novel drugs for CML are still expected. ZSTK474 is a specific phosphatidylinositol 3-kinase (PI3K) inhibitor that we identified. In the present study, the efficacy of ZSTK474, alone or in combination with Imatinib, on K562 CML cells as well as on its multidrug resistance counterpart K562/A02 cells, was investigated. ZSTK474 inhibited the cell proliferation with an IC50 of 4.69 muM for K562 and 7.57 muM for K562/A02 cells, respectively. Treatment by ZSTK474 resulted in cell cycle arrest in G1 phase, which might be associated with upregulation of p27, and downregulation of cyclin D1. ZSTK474 also inhibited phosphorylation of Akt and GSK-3beta, which might be involved in the effect on the above cell cycle-related proteins. Moreover, combination of ZSTK474 and Imatinib indicated synergistic effect on both cell lines. In conclusion, ZSTK474 exhibited antileukemia activity alone, and showed synergistic effect when combined with Imatinib, on CML K562 cells as well as the multidrug resistant ones, providing a potential therapeutic approach for CML patients.
Synergistic antitumour activity of RAF265 and ZSTK474 on human TT medullary thyroid cancer cells.[Pubmed:26081844]
J Cell Mol Med. 2015 Sep;19(9):2244-52.
Medullary thyroid cancer (MTC) is an aggressive malignancy responsible for up to 14% of all thyroid cancer-related deaths. It is characterized by point mutations in the rearranged during transfection (RET) proto-oncogene. The activated RET kinase is known to signal via extracellular signal regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K), leading to enhanced proliferation and resistance to apoptosis. In the present work, we have investigated the effect of two serine/threonine-protein kinase B-Raf (BRAF) inhibitors (RAF265 and SB590885), and a PI3K inhibitor (ZSTK474), on RET-mediated signalling and proliferation in a MTC cell line (TT cells) harbouring the RETC634W activating mutation. The effects of the inhibitors on VEGFR2, PI3K/Akt and mitogen-activated protein kinases signalling pathways, cell cycle, apoptosis and calcitonin production were also investigated. Only the RAF265+ ZSTK474 combination synergistically reduced the viability of treated cells. We observed a strong decrease in phosphorylated VEGFR2 for RAF265+ ZSTK474 and a signal reduction in activated Akt for ZSTK474. The activated ERK signal also decreased after RAF265 and RAF265+ ZSTK474 treatments. Alone and in combination with ZSTK474, RAF265 induced a sustained increase in necrosis. Only RAF265, alone and combined with ZSTK474, prompted a significant drop in calcitonin production. Combination therapy using RAF265 and ZSTK47 proved effective in MTC, demonstrating a cytotoxic effect. As the two inhibitors have been successfully tested individually in clinical trials on other human cancers, our preclinical data support the feasibility of their combined use in aggressive MTC.
Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury.[Pubmed:27549161]
J Neuroinflammation. 2016 Aug 22;13(1):192.
BACKGROUND: Microglia/macrophages play a critical role in the inflammatory and immune processes of cerebral ischemia/reperfusion injury. Since microglia/macrophages can reversibly shift their phenotype toward either a "detrimental" or a "restorative" state in the injured central nervous system (CNS), compounds mediate that shift which could inhibit inflammation and restore the ability to alleviate cerebral ischemia/reperfusion injury would have therapeutic potential. METHODS: Transient middle cerebral artery occlusion was induced in male C57BL/6 mice. Mice were randomly separated into a sham-operated group, a control group, and a ZSTK474-treated group. We investigated the effect of ZSTK474 by assessing neurological deficits, infarct volume, and histopathological changes. We then determined the potential mechanism by immunofluorescent staining, quantitative real-time polymerase chain reaction (PCR), and Western blot analysis. The Tukey's test or Mann-Whitney U test was used to compare differences among the groups. RESULTS: ZSTK474 alleviated neurological deficits and reduced infarct volume in the cerebral ischemia/reperfusion injury model. Presumably, ZSTK474 shifted the phenotype of microglia/macrophages to a restorative state, since this treatment decreased the secretion of pro-inflammatory factors and advanced the secretion of anti-inflammatory factors. These neuroprotective properties of ZSTK474 may be mediated by the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin complex 1 (mTORC1) pathway. CONCLUSIONS: ZSTK474 can mediate a shift in microglia/macrophage phenotype and inhibit the inflammatory response in cerebral ischemia reperfusion injury of mice. These effects appeared to ensue via the PI3K/AKT/mTORC1 pathway. Therefore, ZSTK474 may represent a therapeutic intervention with potential for circumventing the catastrophic aftermath of ischemic stroke.